CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

204300Orig1s000

MICROBIOLOGY / VIROLOGY REVIEW(S)

Product Quality Microbiology Review

11 March 2014

NDA: 204300

Drug Product Name
Proprietary: Not applicable
Non-proprietary: Phenylephrine Hydrochloride Injection, 1%, USP

Review Number: 1

Dates of Submission(s) Covered by this Review

Submit	Received	Review Request	Assigned to Reviewer
28 June 2013	28 June 2013	17 July 2013	19 July 2013
23 December 2013	23 December 2013	N/A	N/A
11 February 2014	11 February 2014	N/A	N/A
7 March 2014	7 March 2014	N/A	N/A

Applicant/Sponsor
Name: Eclat Pharmaceuticals
Address: 699 Trade Center Blvd.
Suite A
Chesterfield, MO 63005

Representative: Marla E. Scarola
Telephone: 202-730-4129

Name of Reviewer: Stephen E. Langille, Ph.D.

Conclusion: Recommended for Approval

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: 505(b)2

2. SUBMISSION PROVIDES FOR: Original application

3. MANUFACTURING SITE: (b) (4)

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:

- Sterile Solution
- Intravenous Injection
- 10 mg/mL
- (b) (4) and 10 mL Type 1 clear glass vials

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: Treatment of hypotension during anesthesia.

B. SUPPORTING/RELATED DOCUMENTS: Not applicable

C. REMARKS: The document was provided in eCTD format. Several information requests were sent to the applicant during the course of this review.

filename: N204300r1.doc

Reference ID: 3469777

Executive Summary

I. Recommendations

A. Recommendation on Approvability - Recommended for Approval

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable –
Not applicable

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology -
The drug product is provided in 1 mL, 5 mL, and 10 mL presentations and [redacted] (b) (4).

B. Brief Description of Microbiology Deficiencies -
No deficiencies were identified based upon the information provided.

C. Assessment of Risk Due to Microbiology Deficiencies –
Not applicable

D. Contains Potential Precedent Decision(s)- ☐ **Yes** ☒ **No**
(If yes, provide a brief description and a reference to the page where the precedent is discussed in depth)

III. Administrative

A. Reviewer's Signature _____
Stephen E. Langille, Ph.D.
Senior Microbiology Reviewer

B. Endorsement Block
John Metcalfe, Ph.D. – Senior Microbiology Reviewer

C. CC Block
N/A

11 Page(s) has been Withheld in Full as b4 (CCI/TS) immediately following this page

Reference ID: 3469777

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEPHEN E LANGILLE
03/12/2014

JOHN W METCALFE
03/12/2014
I concur.

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 204300 | **Applicant:** Eclat Pharmaceuticals | **Letter Date:** 28 June 2013

Drug Name: Phenylephrine Hydrochloride Injection, 1% | **NDA Type:** 505(b)(2) resubmission resulting from RTF letter. | **Stamp Date:** 28 June 2013

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	X		
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		
7	Has the applicant submitted the results of analytical method verification studies?		X	No sterility or endotoxin verification study results
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	X		No such studies were requested.
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments:
The following information request should be conveyed to the applicant in the 74 day letter:

Provide the results of verification studies to support the endotoxin and sterility test protocols referenced in the drug product specification.

Stephen E. Langille, Ph.D. Date
Senior Microbiology Reviewer

John Metcalfe, Ph.D. Date
Senior Microbiology Reviewer

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEPHEN E LANGILLE
08/05/2013

JOHN W METCALFE
08/05/2013
I concur.

PRODUCT QUALITY MICROBIOLOGY FILING CHECKLIST

NDA Number: 204300 | **Applicant:** Eclat Pharmaceuticals | **Letter Date:** 8 February 2013

Drug Name: Phenylephrine Hydrochloride Injection, 1% | **NDA Type:** 505(b)(2) | **Stamp Date:** 8 February 2013

The following are necessary to initiate a review of the NDA application:

	Content Parameter	Yes	No	Comments
1	Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?	X		
2	Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?	X		
3	Has the applicant submitted protocols and results of validation studies concerning microbiological control processes used in the manufacture of the drug product?	X		
4	Are any study reports or published articles in a foreign language? If yes, has the translated version been included in the submission for review?		X	
5	Has the applicant submitted preservative effectiveness studies (if applicable) and container-closure integrity studies?	X		
6	Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?	X		
7	Has the applicant submitted the results of analytical method verification studies?		X	No sterility or endotoxin verification study results
8	Has the applicant submitted all special/critical studies/data requested during pre-submission meetings and/or discussions?	X		No such studies were requested.
9	Is this NDA fileable? If not, then describe why.	X		

Additional Comments:
The following information request should be conveyed to the applicant in the 74 day letter:

Provide the results of verification studies to support the endotoxin and sterility test protocols referenced in the drug product specification.

Stephen E. Langille, Ph.D. Microbiology Reviewer	Date
Bryan Riley, Ph.D. Acting Team Leader	Date

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STEPHEN E LANGILLE
02/28/2013

BRYAN S RILEY
02/28/2013
I concur.